Compare MYE & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYE | EVO |
|---|---|---|
| Founded | 1933 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 826.0M | 934.1M |
| IPO Year | 1995 | N/A |
| Metric | MYE | EVO |
|---|---|---|
| Price | $22.84 | $3.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $26.00 | $7.00 |
| AVG Volume (30 Days) | ★ 166.4K | 98.7K |
| Earning Date | 05-07-2026 | 04-08-2026 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | ★ 389.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.87 | $1.37 |
| Revenue Next Year | $1.83 | $10.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.86 | $2.31 |
| 52 Week High | $24.25 | $4.80 |
| Indicator | MYE | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 61.09 | 51.20 |
| Support Level | $20.03 | $2.88 |
| Resistance Level | $24.03 | $3.78 |
| Average True Range (ATR) | 0.92 | 0.12 |
| MACD | 0.22 | -0.02 |
| Stochastic Oscillator | 67.89 | 29.41 |
Myers Industries Inc designs, manufactures, and markets a variety of plastic, metal, and rubber products, including a broad selection of plastic reusable containers, pallets, small parts bins, bulk shipping containers, storage and organization products, OEM parts, custom plastic products, consumer fuel containers and tanks for water, fuel and waste handling. It operates through the following segments: The Material Handling segment manufactures a selection of durable plastic reusable products that are used repeatedly during the course of their service life. The Distribution segment is engaged in the distribution of equipment, tools, and supplies used for tire servicing and automotive under-vehicle repair, etc. It generates the majority of its revenue from the Material Handling segment.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.